Endogenous immune response to early- and intermediate-stage melanoma is correlated with outcomes and is independent of locoregional relapse and standard prognostic factors

Journal of the American College of Surgeons

Volumn 198, Issue 1, 2004, Pages 27-35

  Litvak, David A ^a,b   Gupta, Rishab K ^a   Yee, Reynold ^a   Wanek, Leslie A ^a   Ye, Wei ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MELANOMA ANTIGEN; TA90 MELANOMA ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; IMMUNE RESPONSE; LYMPH NODE; MELANOMA; METASTASIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS;

EID: 1042275877     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2003.08.012     Document Type: Article

References (40)

1. Wanek L.A., Elashoff R.M., Goradia T.M., et al. Application of multistage Markov modeling to malignant melanoma progression. Cancer. 73:1994;336-343.
2. Barth A., Wanek L.A., Morton D.L. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 181:1995;193-201.
3. Balch C.M., Buzaid A.C., Soong S.J., et al. Final version of the AJCC staging system for cutaneous melanoma. J Clin Oncol. 19:2001;3635-3648.
4. Balch C.M., Soong S.-J., Gershenwald J.E., et al. Prognostic factors analysis of 17,600 melanoma patients validation of the American Joint Committee on Cancer melanoma staging system . J Clin Oncol. 19:2001;3622-3634.
5. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma the Eastern Cooperative Oncology group Trial EST 1684 . J Clin Oncol. 14:1996;7-17.
6. Morton D.L., Foshag L.J., Hoon D.S., et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg. 216:1992;463-482.
7. Pehamberger H., Soyer H.P., Steiner A., et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative group. J Clin Oncol. 16:1998;1425-1429.
8. Shen P., Foshag L., Essner R., et al. Postoperative adjuvant therapy using a polyvalent melanoma vaccine improves overall survival of patients with primary melanoma. [abstract] Proc Am Soc Clin Oncol. 18:1999;533a.
9. Sahin S., Rao B., Kopf A.W., et al. Predicting ten-year survival of patients with primary cutaneous melanoma corroboration of a prognostic model . Cancer. 80:1997;1426-1431.
10. Karakousis C.P., Driscoll D.L. Prognostic parameters in localised melanoma gender versus anatomical location . Eur J Cancer. 31A:1995;320-324.
11. Austin P.F., Cruse C.W., Lyman G., et al. Age as a prognostic factor in the malignant melanoma population. Ann Surg Oncol. 1:1994;487-494.
12. Kelley M.C., Gupta R.K., Hsueh E.C., et al. Tumor-associated antigen TA90 immune complex assay predicts recurrence and survival after surgical treatment of stage I-III melanoma. J Clin Oncol. 19:2001;1176-1182.
13. Kelley M.C., Jones R.C., Gupta R.K., et al. Tumor-associated antigen TA-90 immune complex assay predicts subclinical metastasis and survival for patients with early-stage melanoma. Cancer. 83:1998;1355-1361.
14. Gupta R.K., Morton D.L. Monoclonal antibody-based ELISA to detect glycoprotein tumor-associated antigen-specific immune complexes in cancer patients. J Clin Lab Anal. 6:1992;329-336.
15. Euhus D.M., Gupta R.K., Morton D.L. Characterization of a 90-100kDa tumor-associated antigen in the sera of melanoma patients. Int J Cancer. 45:1990;1065-1070.
16. Rote N.S., Gupta R.K., Morton D.L. Tumor-associated antigens detected by autologous sera in urine of patients with solid neoplasms. J Surg Res. 29:1980;18-22.
17. Gupta R.K. Circulating immune complexes in malignant melanoma. Disease Markers. 6:1988;81-96.
18. Euhus D.M., Gupta R.K., Morton D.L. Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine. Cancer Immunol Immunother. 29:1989;247-254.
19. Habal N., Gupta R.K., Bilchik A.J., et al. TA90-IC, a new marker for advanced colon cancer. Ann Surg Oncol. 7:2000;352-356.
20. Hsueh E.C., Gupta R.K., Yee R., et al. Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma? Ann Surg Oncol. 7:2000;232-238.
21. Hsueh E.C., Gupta R.K., Qi K., et al. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma. Cancer J Sci Am. 3:1997;364-370.
22. Hsueh E.C., Gupta R.K., Qi K., Morton D.L. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol. 16:1998;2913-2920.
23. Balch C.M., Soong S.J., Smith T., et al. Long-term results of a prospective surgical trial comparing 2 cm versus 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol. 8:2001;101-108.
24. Chung M.H., Gupta R.K., Essner R., et al. Serum TA90 immune complex assay can predict outcome after resection of thick (greater than 4 mm) primary melanoma and sentinel lymphadenectomy. Ann Surg Oncol. 9:2002;120-126.
25. Peterson L.L., Woodward W.R., Fletcher W.S., et al. Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects. J Am Acad Dermatol. 19:1988;509-515.
26. Guo H.B., Stoffel-Wagner B., Bierwirth T., et al. Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer. 31A:1995;1898-1902.
27. Martenson E.D., Hansson L.O., Nilsson B., et al. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol. 19:2001;824-831.
28. Lorenz J., Dippold W. Neuron-specific enolase - a serum marker for malignant melanoma. J Natl Cancer Inst. 81:1989;1754-1755.
29. Deichmann M., Benner A., Bock M., et al. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol. 17:1999;1891-1896.
30. Bostick P.J., Morton D.L., Turner R.R., et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol. 17:1999;3238-3244.
31. Hoon D.S., Bostick P., Kuo C., et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res. 60:2000;2253-2257.
32. Smith B., Selby P., Southgate J., et al. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet. 338:1991;1227-1229.
33. Livingston P.O., Wong G.Y., Adluri S., et al. Improved survival in stage III melanoma patients with GM2 antibodies a randomized trial of adjuvant vaccination with GM2 ganglioside . J Clin Oncol. 12:1994;1036-1044.
34. Jones P.C., Sze L.L., Liu P.Y., et al. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst. 66:1981;249-254.
35. Jones R.C., Kelley M.C., Gupta R.K., et al. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma an immunologic survival model . Ann Surg Oncol. 3:1996;437-445.
36. DiFronzo L.A., Gupta R.K., Essner R., et al. Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J Clin Oncol. 20:2002;3242-3248.
37. Ollert M.W., David K., Schmitt C., et al. Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells. Proc Natl Acad Sci USA. 93:1996;4498-4503.
38. David K., Ollert M.W., Vollmert C., et al. Human natural immunoglobulin M antibodies induce apoptosis of human neuroblastoma cells by binding to a Mr 260,000 antigen. Cancer Res. 59:1999;3768-3775.
39. Hunt K.K., Shibata M., Gupta R.K., Morton D.L. Complement-dependent lysis of tumor cells by a baboon IgM antibody to a tumor-associated antigen. Cancer Immunol Immunother. 34:1992;377-382.
40. Hsueh E.C., Famatiga E., Gupta R.K., et al. Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (CancerVax) correlation with survival . Ann Surg Oncol. 5:1998;595-602.